Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656273 | 0.77 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL6120988 | 0.76 | GRIN2D (0.38) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL15177092 | 0.75 | OPRM1 (0.40) | OPRM1 | |
| SCHEMBL5360575 | 0.74 | GRIN2D (0.41) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL22063472 | 0.74 | GRIN2D (0.37) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL18323029 | 0.74 | GRIN2D (0.37) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL680859 | 0.74 | GRIN2D (0.43) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL12445305 | 0.74 | GRIN2D (0.43) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL680288 | 0.72 | GRIN2D (0.42) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL3646367 | 0.71 | GRIN2D (0.35) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | IMAGO BIOSCIENCES, INC. | 2019-03-07 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-8507494-B2 | Heterocyclic quinolizine derived M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130040959-A1 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME LLC | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070172-A1 | LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS | KDM1B, KDM1A, KDM2A | GRIN2D 4612/4885GRIN3B 4240/4885CHRM2 4246/4885 |
| US-20130040959-A1 | Heterocyclic Quinolizine Derived M1 Receptor Positive Allosteric Modulators | CHRM1, OPRL1, CHRNA5 | GRIN2D 156/4885GRIN3B 135/4885CHRM2 5/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | GRIN2D 4053/4885GRIN3B 2938/4885CHRM2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.